Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US-9695233-B2 · Jul 4, 2017 · US
Heavy chain only antibodies to ANG-2
US10266589B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10266589-B2 |
| Application number | US-201615223855-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 29, 2016 |
| Priority date | Jul 29, 2015 |
| Publication date | Apr 23, 2019 |
| Grant date | Apr 23, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to ANG-2 and bispecific antibodies with antigen-binding specificities to ANG-2 and VEGF or PDGF.
First claim
Opening claim text (preview).
What is claimed is: 1. A heavy chain only antibody (HCAb) with an antigen-binding specificity for ANG-2, wherein the HCAb comprises three complementarity determining regions (CDR), wherein: the first CDR (CDR1) comprises SEQ ID NO:12; the second CDR (CDR2) comprises SEQ ID NO:14; and the third CDR (CDR3) comprises one of SEQ ID NOs:16, 28, or 31. 2. The HCAb of claim 1 , wherein CDR3 comprises SEQ ID NO.16. 3. The HCAb of claim 1 , wherein CDR3 comprises SEQ ID NO:28. 4. The HCAb of claim 1 , wherein CDR3 comprises SEQ ID NO:31. 5. A HCAb with an antigen-binding specificity for ANG-2, wherein the HCAb comprises three CDRs, wherein CDR1 comprises SEQ ID NO:32, CDR2 comprises SEQ ID NO:33, and CDR3 comprises SEQ ID NO:34. 6. A HCAb with an antigen-binding specificity for ANG-2, wherein the HCAb comprises three CDRs, wherein CDR1 comprises SEQ ID NO:35, CDR2 comprises SEQ ID NO:36, and CDR3 comprises SEQ ID NO:37.
Assignees
Inventors
Classifications
Ophthalmic agents · CPC title
Hinge · CPC title
- C07K16/22Primary
against growth factors {; against growth regulators} · CPC title
variable (Fv) region, i.e. VH and/or VL · CPC title
Framework region [FR] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10266589B2 cover?
- Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to ANG-2 and bispecific antibodies with antigen-binding specificities to ANG-2 and VEGF or PDGF.
- Who is the assignee on this patent?
- Allergan Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).